Replicel’s cell therapy candidate RCT-01 shows treatment effect in patients with degenerated Achilles tendon – Seeking Alpha

Results from an eight-subject Phase 1/2 clinical trial, ReaCT, assessing a single injection of Replicel Life Sciences' (OTCQB:REPCF) RCT-01 into the Achilles tendon of patients with Achilles tendinosis showed clinically important improvements including pain sensation, physical function, blood supply and tendon composition.

Achilles tendinosis is a degenerative process of the tendon that does to present with signs like inflammation either clinically or by examining tissue samples under a microscope, but is associated with pain and loss of function. There are no effective therapies for the condition.

Participants showed clinically relevant signs of healing six months after injection as measured by an overall 15.3% improvement in a scale called VISA-A. Two patients achieved almost total recovery. Four of five patients who completed questionnaires showed relevant signs of improvement in pain on loading (running/jumping) based on a scale called VAS. The average improvement in VAS score from baseline was 62.9%. Three of the five patients experienced improvements in pain on palpation (feeling the tendon with the hands during a physical exam). The average improvement in VAS score from baseline was 55.2%.

All study participants except one experienced at least one adverse event, either injection site soreness or observation of a partial thickness tear in the tendon after the injection.

RCT-01 is an autologous cell therapy that uses non-bulbar dermal sheath cells isolated from the hair follicle sheath. Developmentis ongoing.

Here is the original post:
Replicel's cell therapy candidate RCT-01 shows treatment effect in patients with degenerated Achilles tendon - Seeking Alpha